3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
167
Triple Negative Breast Neoplasms
14
Neoplasm Metastasis
13
Carcinoma, Non-Small-Cell Lung
7
Neoplasms
6
Breast Neoplasms, Male
5
Brain Neoplasms
4
Prostatic Neoplasms
3
Ovarian Neoplasms
3
HER2-positive Advanced Breast Cancer
3
Advanced Breast Cancer
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
HER2-negative Breast Cancer
2
HER2 Positive Breast Cancer
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Primary Breast Cancer
1
Pheochromocytoma
1
Patient Acceptance of Health Care
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma, Extra-Adrenal
1
Metastatic HER2-positive Breast Cancer
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Inflammatory Breast Neoplasms
1
Hormone Receptor Positive Advanced Breast Cancer
1
Interventions
pembrolizumab
6
Paclitaxel
3
Docetaxel
3
Cyclophosphamide
3
eribulin
2
Oncolytic Virotherapy
2
tislelizumab
1
tirbanibulin
1
spartalizumab
1
poly ICLC
1
pertuzumab
1
pemigatinib
1
pegfilgrastim
1
obinutuzumab
1
ixabepilone
1
fludarabine phosphate
1
fludarabine
1
etirinotecan pegol
1
efineptakin alfa
1
durvalumab
1
atezolizumab
1
aldesleukin
1
advexin
1
Yoga
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Surveys and Questionnaires
1
Ritonavir
1
Radiotherapy
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Vinorelbine
×
Breast
×
Clear all
NCT02915744
2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3
Completed
178 enrolled
37 charts